Abstracts tagged "Biologic drugs"

Abstract Number: 464 • 2015 ACR/ARHP Annual Meeting
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis
Cheryl Barnabe¹, Yufei Zheng², Arto Ohinmaa², Brenda Hemmelgarn³, Gilaad Kaplan⁴, Liam Martin⁵ and Walter Maksymowych⁶, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Institute of Health Economics, Edmonton, AB, Canada, ³Division of Nephrology, University of Calgary, Calgary, AB, Canada, ⁴Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Medicine, Medicine, University of Alberta, Edmonton, AB, Canada
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis Background/Purpose: Aboriginal people with rheumatoid arthritis (RA) have more severe disease and an…
Abstract Number: 2336 • 2015 ACR/ARHP Annual Meeting
Literature Review of Patient Reported Outcome and Health Related Quality of Life Measures for Biologic Therapies in the Management of Psoriatic Arthritis and Ankylosing Spondylitis
Steffen Jugl¹, Sultana Syeda² and Gunda Praveen², ¹BF I&D GPA, Health Economics and Outcomes Research, Novartis Pharma AG, Basel, Switzerland, ²Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India
Background/Purpose: Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are chronic progressive conditions with substantial humanistic burden on patients and care givers. A variety of instruments,…
Abstract Number: 500 • 2015 ACR/ARHP Annual Meeting
Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis
Vidhu Anand¹, Sachit Anand², Sushil Garg³, Maria A. Lopez-Olivo⁴ and Jasvinder A. Singh⁵, ¹University of Minnesota, Minneapolis, MN, ²All India Institute of Medical Sciences, New Delhi, India, ³The University of Minnesota, Minneapolis, MN, ⁴General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Ofatumumab is a unique anti-CD20 monoclonal antibody with its epitope more proximal and distinct from the epitope recognized by rituximab or by other anti-CD20…
Abstract Number: 2522 • 2015 ACR/ARHP Annual Meeting
High Risk of Flares during Pregnancy in Women with Rheumatoid Arthritis Who Discontinue Treatment with TNF Inhibitors at Conception
Rebecca Fischer-Betz¹, Oliver Sander¹, Christof Specker², Ralph Brinks³ and Matthias Schneider¹, ¹Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ²Rheumatology and clinical immunology, Kliniken Essen Sued, Essen, Germany, ³Hiller Center for Research in Rheumatology, Duesseldorf, Germany
Background/Purpose: Optimal treatment of women with Rheumatoid Arthritis (RA) during pregnancy remains a challenge, mainly due to safety concerns. TNF inhibitors (TNFi) are now routinely…
Abstract Number: 511 • 2015 ACR/ARHP Annual Meeting
Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient
KAZUYUKI YOSHIZAKI, Organic Fine Chemicals, The Institute of Scientific and Industrial Research, Osaka University, Suita, Japan
Background/Purpose: In clinical practice in rheumatoid arthritis (RA), it has been noted that each anti-rheumatic therapy delivers a different outcome for individual RA patients and…
Abstract Number: 2557 • 2015 ACR/ARHP Annual Meeting
Comparable Therapeutic Potential of Umbilical Cord Mesenchymal Stem Cells in Collagen Induced Arthritis with Anti-Tumor Necrosis Factor or Anti-CD20
Yue Sun, Wei Kong, Weiwei Chen, Genhong Yao, Xuebing Feng and Lingyun Sun, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Tremendous progress has been made in the development of non-conventional therapies for rheumatoid arthritis (RA). Mesenchymal stem cells (MSC) present multiple immunosuppressive capacities and…
Abstract Number: 517 • 2015 ACR/ARHP Annual Meeting
Investigating Psychological Predictors of Biologic Treatment Response in Patients with Severe Active Rheumatoid Arthritis
Bethan England¹, Lis Cordingley², Darren Plant³, Ann Morgan⁴, Anthony Wilson⁵, Kimme L. Hyrich⁶, Anne Barton⁷ and BRAGGSS Syndicate, ¹University of Manchester, Manchester, United Kingdom, ²School of Community Based Medicine, University of Manchester, Manchester, United Kingdom, ³arc Epidemiology Unit, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁵Genomic Medicine, The University of Sheffield, Sheffield, United Kingdom, ⁶Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Biologic therapy is now a cornerstone of RA management, but treatment response is variable, failing in up to 40% of patients. To direct appropriate…
Abstract Number: 2640 • 2015 ACR/ARHP Annual Meeting
Factors Influencing Treatment Adjustments in RA Patients – Biologic DMARD Treatment Start and Options
Peter C. Taylor¹, Emma Sullivan², Robert Wood³, James Piercy³, Rieke Alten⁴, Juan J Gomez-Reino⁵, Philippe Bertin⁶, Roberto Caporali⁷, Radu Vasilescu⁸, Dean Spurden⁹ and Jose Alvir¹⁰, ¹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, ²Adelphi Real World, Manchester, United Kingdom, ³Adelphi Real World, Macclesfield, United Kingdom, ⁴Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁵Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, ⁶Rheumatology, CHU Dupuytren, Limoges, France, ⁷University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁸Medical Affairs, Pfizer Inc, Brussels, Belgium, ⁹Pfizer Inc, Tadworth, United Kingdom, ¹⁰Global Health and Value, Pfizer Inc, New York, NY
Background/Purpose: Current recommendations for pharmacologic management of rheumatoid arthritis (RA) advise dose titration or switching treatment if goals of remission or low disease activity are…
Abstract Number: 549 • 2015 ACR/ARHP Annual Meeting
Calprotectin (MRP8/MRP14), a Major Leukocyte Protein, Is Highly Associated to Ultrasound Detected Synovitis and Is Responsive to Biologic Treatment
Hilde Berner Hammer¹, Hilde Haugedal Nordal^2,3 and Tore K. Kvien⁴, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept of Rheumatology, Haukeland Univerity Hospital, Bergen, Norway, ³Department of Clinical Science, University of Bergen, Broegelmann Research Laboratory, Bergen, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Calprotectin (MRP8/MRP14, S100A8/A9) is a protein abundant in cytosol of granulocytes and monocytes/macrophages and released during cell activation. It reflects clinical disease activity in…
Abstract Number: 2641 • 2015 ACR/ARHP Annual Meeting
Correlation of Rheumatologists’ Perceptions of RA Severity with Observed Disease Activity, Patient Impact and Treatment Patterns
Peter C. Taylor¹, Juan J Gomez-Reino², Roberto Caporali³, Rieke Alten⁴, Philippe Bertin⁵, Emma Sullivan⁶, Robert Wood⁷, James Piercy⁷, Radu Vasilescu⁸, Dean Spurden⁹ and Jose Alvir¹⁰, ¹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, ²Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, ³University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁴Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁵Rheumatology, CHU Dupuytren, Limoges, France, ⁶Adelphi Real World, Manchester, United Kingdom, ⁷Adelphi Real World, Macclesfield, United Kingdom, ⁸Medical Affairs, Pfizer Inc, Brussels, Belgium, ⁹Pfizer Inc, Tadworth, United Kingdom, ¹⁰Global Health and Value, Pfizer Inc, New York, NY
Background/Purpose: Efforts have been made in recent years to standardize the clinical assessment of RA patients with increased focus on objective measures, such as the…
Abstract Number: 582 • 2015 ACR/ARHP Annual Meeting
Biological Drugs Dose Tapering in Inflammatory Rheumatic Diseases: 2 Year Results at Basurto University Hospital
Juan María Blanco-Madrigal¹, Maria Luz Garcia Vivar¹, Catalina Gomez Arango¹, Olaia Fernández Berrizbeitia¹, Clara Perez Velasquez¹, Ignacio Torre Salaberri², Jose Francisco Garcia Llorente³, Eva Galindez-Agirregoikoa⁴, Esther Ruiz Lucea¹ and Iñigo Gorostiza⁵, ¹Rheumatology, Basurto University Hospital, Bilbao, Spain, ²Rheumaytology, Basurto University Hospital, Bilbao, Spain, ³Rheumatology, Basurto University Hospital., Bilbao, Spain, ⁴Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ⁵Research Department, BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain
Background/Purpose: Last years, biological dose tapering in patients with inflammatory diseases has become a routine clinical practice. Since 2011 we are applying a dose reduction…
Abstract Number: 2667 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Health Outcomes of RA Patients Not Adequately Controlled By Current Treatment
Peter C. Taylor¹, Rieke Alten², Philippe Bertin³, Roberto Caporali⁴, Juan J Gomez-Reino⁵, Emma Sullivan⁶, Robert Wood⁷, James Piercy⁷, Radu Vasilescu⁸, Dean Spurden⁹ and Jose Alvir¹⁰, ¹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, ²Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³Rheumatology, CHU Dupuytren, Limoges, France, ⁴University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁵Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, ⁶Adelphi Real World, Manchester, United Kingdom, ⁷Adelphi Real World, Macclesfield, United Kingdom, ⁸Medical Affairs, Pfizer Inc, Brussels, Belgium, ⁹Pfizer Inc, Tadworth, United Kingdom, ¹⁰Global Health and Value, Pfizer Inc, New York, NY
Background/Purpose: Despite an increasing armamentarium of efficacious treatments for Rheumatoid Arthritis (RA), sustained remission remains an unrealistic expectation for many patients, with most experiencing ongoing…
Abstract Number: 2123 • 2014 ACR/ARHP Annual Meeting
Significant State-Level Variation in Source of Biologic Drug Coverage Among Beneficiaries with Rheumatoid Arthritis
Chris Tonner¹, Gabriela Schmajuk² and Jinoos Yazdany², ¹3333 California Street, Box 09, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Biologic drugs can be obtained both through Medicare's Part B medical benefit (physician administered drugs) or Part D pharmacy benefit (self-administered drugs). Coverage for…
Abstract Number: 483 • 2014 ACR/ARHP Annual Meeting
Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience
Francesca De Nard¹, Vittorio Grosso², Monica Todoerti³, Carlomaurizio Montecucco⁴ and Roberto Caporali⁵, ¹Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Division of Rheumatology, University of Pavia, Foundation IRCCS Policlinico S. Matteo, Pavia, Italy, ³Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁴Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ⁵Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose HBV infection represents a major issue in patients with rheumatoid arthritis (RA) undergoing biological disease-modifying anti-rheumatic drugs (bDMARDs) (1). While the risk of hepatitis…
Abstract Number: 2040 • 2014 ACR/ARHP Annual Meeting
Opportunistic Infections in Patients Treated with Biologic Drug Therapy
Laura Encinas¹, Maria Haye Salinas¹, Veronica Saurit¹, Alejandro J. Alvarellos², Francisco Caeiro¹, Cristina Battagliotti³, Ida Elena Exeni⁴, Carla Gobbi⁵, Bernardo Pons-Estel⁶, Ingrid Strusberg⁷, Sergio Paira⁸, Eduardo Mussano⁹, Maria Apaz¹⁰, Ana Quinteros¹¹, Ana Capuccio¹², Mercedes De La Sota¹³, Maria Larroude¹⁴, Amelia Granel¹⁵, Oscar Rillo¹⁶, Enrique Soriano¹⁷, Gustavo Citera¹⁸, Diana Dubinsky¹⁹, Mari Delgado²⁰, Analia Alvarez²¹, Graciela Gómez²², Gustavo Casado²³, Santiago Aguero²⁴, Monica Sacnum²⁰, Mercedes Garcia²⁰, Sidney Soares de Souza²⁵, Edson Javier Velozo²⁶, C Paruolo²⁰, Monica Patricia Diaz²⁷, Emilia Cavillion²⁸, Juan C. Barreira²⁹, Gimena Gómez³⁰ and E. Scheines³¹, ¹Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, ²Reumatología, Hospital Privado Córdoba, Córdoba, Argentina, ³Hospital de Niños Dr Orlando Alasia, Santa Fé, Argentina, ⁴Sanatorio Parque, Cordoba, Argentina, ⁵Hospital Còrdoba, Còrdoba, Argentina, ⁶Sanatorio Parque, Rosario, Argentina, ⁷Instituto Reumatológico Strusberg, Cordoba, Argentina, ⁸Section of Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, ⁹Hospital Nacional De Clinicas, Mariquita Sanchez 2304, Buenos Aires, Argentina, ¹⁰Pediatric Rheumatology, Hospital de niños de cordoba, córdoba, Argentina, Argentina, ¹¹Centro Integral de Reumatología, Tucumán, Argentina, ¹²Rheumatology, Hospital cesar Milstein, Buenos Aires, Argentina, ¹³Consultorio, Bahia Blanca, Argentina, ¹⁴Consultorio, Buenos Aires, Argentina, ¹⁵Rheumatology, Hospital San Roque de Gonnet, La Plata, La Plata, Argentina, ¹⁶Rheumatology, Hospital Sirio Libanes, Buenos Aires, Argentina, ¹⁷Hospital Italiano, Buenos Aires, Argentina, ¹⁸Universidad de Buenos Aires, Buenos Aires, Argentina, ¹⁹Rheumatology, Hospital de Clinicas, Jose de San Martin, Capital Federal, Argentina, ²⁰consultorio, Buenos Aires, Argentina, ²¹Cemic, Buenos Aires, Argentina, ²²Diaz Colodrero 2537 8° A, Insituto de Investigaciones Medicas de la UBA, Capital Federal, Argentina, ²³Hospital Militar Central, Buenos Aires, Argentina, ²⁴Pasaje Sanchez Gardel 148, Sanatorio Pasteur, Catamarca, Argentina, ²⁵REUMAR, Buenos Aires, Argentina, ²⁶25 DE MAYO 255 -LIBERTADOR SAN, Sanatorio Adventista Del Plata, Entre Rios, Argentina, ²⁷Espana 327, consultorio, Bariloche, Argentina, ²⁸Consultorio, Cordoba, Argentina, ²⁹Rheumatology, British Hospital, Buenos Aires, Argentina, ³⁰Hospital Argerich, Buenos Aires, Argentina, ³¹Rheumatology, Hospital Manuel Rocca, Ciudad Autonoma de Buenos Aires, Argentina
Background/Purpose Biological drug therapy is frequently used to treat autoimmune diseases.These drugs have an increased risk of infections, among them opportunistic infections.To evaluate the frequency…

« Previous Page
1
…
8
9
10
11
12
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].